BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22868923)

  • 21. Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling.
    Shaknovich R; Basso K; Bhagat G; Mansukhani M; Hatzivassiliou G; Murty VV; Buettner M; Niedobitek G; Alobeid B; Cattoretti G
    Haematologica; 2006 Oct; 91(10):1313-20. PubMed ID: 17018379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
    Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
    Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
    Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simian virus 40 in posttransplant lymphoproliferative disorders.
    Vilchez RA; Jauregui MP; Hsi ED; Novoa-Takara L; Chang CC
    Hum Pathol; 2006 Sep; 37(9):1130-6. PubMed ID: 16938517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
    Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
    Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pattern analysis of Epstein-Barr virus viremia and its significance in the evaluation of organ transplant patients suspected of having posttransplant lymphoproliferative disorders.
    Cho YU; Chi HS; Jang S; Park SH; Park CJ
    Am J Clin Pathol; 2014 Feb; 141(2):268-74. PubMed ID: 24436276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease.
    Montone KT; Hodinka RL; Salhany KE; Lavi E; Rostami A; Tomaszewski JE
    Mod Pathol; 1996 Jun; 9(6):621-30. PubMed ID: 8782198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between EBV infection and expression of cellular proteins c-Myc, Bcl-2, and Bax in gastric carcinomas.
    Lima MA; Ferreira MV; Barros MA; Pardini MI; Ferrasi AC; Mota RM; Rabenhorst SH
    Diagn Mol Pathol; 2008 Jun; 17(2):82-9. PubMed ID: 18382371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus (EBV) genotypes among human immunodeficiency virus (HIV)-related B-cell lymphomas and B-cell post-transplant lymphoproliferative disorders (B-PTLD)--late-onset lymphomas, especially in the HIV setting, are associated with type-B-EBV.
    Ibrahim HA; Menasce LP; Pomplun S; Burke M; Bower M; Naresh KN
    Eur J Haematol; 2010 Sep; 85(3):227-30. PubMed ID: 20408873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases.
    Haque T; Chaggar T; Schafers J; Atkinson C; McAulay KA; Crawford DH
    J Med Virol; 2011 Feb; 83(2):311-6. PubMed ID: 21181928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
    Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
    Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EBV load in whole blood correlates with LMP2 gene expression after pediatric heart transplantation or allogeneic hematopoietic stem cell transplantation.
    Ruf S; Behnke-Hall K; Gruhn B; Reiter A; Wagner HJ
    Transplantation; 2014 May; 97(9):958-64. PubMed ID: 24389909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling.
    Menter T; Dickenmann M; Juskevicius D; Steiger J; Dirnhofer S; Tzankov A
    Hematol Oncol; 2017 Jun; 35(2):187-197. PubMed ID: 26799990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders.
    Craig FE; Johnson LR; Harvey SA; Nalesnik MA; Luo JH; Bhattacharya SD; Swerdlow SH
    Diagn Mol Pathol; 2007 Sep; 16(3):158-68. PubMed ID: 17721324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
    Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
    Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
    Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.